Dragovich, P.S., Pillow, T.H., Blake, R.A., Sadowsky, J.D., Adaligil, E., Adhikari, P., Chen, J., Corr, N., Dela Cruz-Chuh, J., Del Rosario, G., Fullerton, A., Hartman, S.J., Jiang, F., Kaufman, S., Kleinheinz, T., Kozak, K.R., Liu, L., Lu, Y., Mulvihill, M.M., Murray, J.M., O’Donohue, A., Rowntree, R.K., Sawyer, W.S., Staben, L.R., Wai, J., Wang, J., Wei, B., Wei, W., Xu, Z., Yao, H., Yu, S.F., Zhang, D., Zhang, H., Zhang, S., Zhao, Y., Zhou, H. and Zhu, X. (2021) Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of in Vitro Antiproliferation Activity and in Vivo Antitumor Efficacy. Journal of Medicinal Chemistry, 64, 2576-2607.
https://doi.org/10.1021/acs.jmedchem.0c01846

has been cited by the following article:

• TITLE: Antibody-Coupled Drugs in HER2-Positive Gastric Cancer

  AUTHORS: Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian

  KEYWORDS: Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.